Summary
69.26 -0.82(-1.17%)07/17/2025
AstraZeneca PLC (AZN)
AZN reported last earnings on 2025-04-29 after the market. An EPS of $1.24 was observed compared to an estimated EPS of $1.1, resulting in a surprise value of $0.14. A revenue of $13,588 million was observed compared to an estimated revenue of $14,058 million, resulting in a surprise value of $-470 Million.
AstraZeneca PLC (AZN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| -0.64 | -2.63 | -2.41 | 2.47 | 5.45 | -11.42 | 32.10 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | B |
| Recommended Rating | Neutral |
| DCF | Buy |
| ROE | Strong Buy |
| ROA | Buy |
| Debt/Equity | Strong Sell |
| P/E | Strong Sell |
| P/B | Strong Sell |
Earnings
| Trading Data | ||
| Close | 68.82 | |
| Open | 69.59 | |
| High | 69.60 | |
| Low | 68.67 | |
| Volume | 2,499,227 | |
| Change | -0.44 | |
| Change % | -0.64 | |
| Avg Volume (20 Days) | 4,067,345 | |
| Volume/Avg Volume (20 Days) Ratio | 0.61 | |
| 52 Week Range | 61.81 - 86.47 | |
| Price vs 52 Week High | -20.41% | |
| Price vs 52 Week Low | 11.34% | |
| Range | 0.00 | |
| Gap Up/Down | -1.17 | |
Profitibility | ||
| Market Capitalization (Mln) | 432,660 | |
| Revenue per share | 17.7361 | |
| Net Income per share | 2.5071 | |
| Dividend Yield | 0.0222 | |
| Dividend Share | 154.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | 55.2512 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
07/17 19:16 EST - zacks.com
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
Astrazeneca (AZN) closed the most recent trading day at $69.26, moving 1.17% from the previous trading session.
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
Astrazeneca (AZN) closed the most recent trading day at $69.26, moving 1.17% from the previous trading session.
07/17 14:10 EST - zacks.com
AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies
AZN's anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.
AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies
AZN's anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.
07/16 03:31 EST - proactiveinvestors.co.uk
AstraZeneca shares open lower after rare disease drug fails to meet main trial goal
AstraZeneca PLC (LSE:AZN) shares opened lower on Wednesday after a late-stage trial of its experimental treatment for AL amyloidosis failed to meet its primary target in the overall patient group. The CARES phase III study tested anselamimab, a drug designed to clear harmful protein deposits in...
AstraZeneca shares open lower after rare disease drug fails to meet main trial goal
AstraZeneca PLC (LSE:AZN) shares opened lower on Wednesday after a late-stage trial of its experimental treatment for AL amyloidosis failed to meet its primary target in the overall patient group. The CARES phase III study tested anselamimab, a drug designed to clear harmful protein deposits in...
07/15 10:45 EST - zacks.com
Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
07/15 09:36 EST - zacks.com
AstraZeneca Meets All Key Goals in Phase III Hypertension Study
AZN hits all endpoints in phase III study for baxdrostat, a first-in-class treatment targeting hard-to-manage hypertension.
AstraZeneca Meets All Key Goals in Phase III Hypertension Study
AZN hits all endpoints in phase III study for baxdrostat, a first-in-class treatment targeting hard-to-manage hypertension.
07/14 10:42 EST - zacks.com
Here's Why Astrazeneca (AZN) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Astrazeneca (AZN) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
07/14 08:50 EST - marketwatch.com
AstraZeneca shares show signs of life after successful trials of hypertension drug
Baxdostat trials showed immense promise for huge available market.
AstraZeneca shares show signs of life after successful trials of hypertension drug
Baxdostat trials showed immense promise for huge available market.
07/14 07:00 EST - businesswire.com
Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the BaxHTN Phase III trial showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) compared with placebo at 12 weeks....
Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the BaxHTN Phase III trial showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) compared with placebo at 12 weeks....
07/11 08:01 EST - proactiveinvestors.co.uk
AstraZeneca and GSK slide on Trump threats but analysts see positive catalysts ahead
Shares in AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK) were both down over 1% on Friday, but the shares are worth buying, analysts at Shore Capital said. Blue-chip shares across London and Europe were lower on Friday, after Donald Trump scaled up his tariff rhetoric again.
AstraZeneca and GSK slide on Trump threats but analysts see positive catalysts ahead
Shares in AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK) were both down over 1% on Friday, but the shares are worth buying, analysts at Shore Capital said. Blue-chip shares across London and Europe were lower on Friday, after Donald Trump scaled up his tariff rhetoric again.
07/10 09:47 EST - proactiveinvestors.co.uk
Trumps 200% tariffs. Here's what it means for UK pharma investors
UBS has flagged a fresh risk for European drugmakers after President Trump said pharmaceuticals imported into the US could soon face tariffs of up to 200%. The comments, made earlier this week, revive concerns over protectionist policies targeting medicines not manufactured on American soil.
Trumps 200% tariffs. Here's what it means for UK pharma investors
UBS has flagged a fresh risk for European drugmakers after President Trump said pharmaceuticals imported into the US could soon face tariffs of up to 200%. The comments, made earlier this week, revive concerns over protectionist policies targeting medicines not manufactured on American soil.
07/09 09:46 EST - proactiveinvestors.co.uk
AstraZeneca: Market isn't pricing in the potential of late-stage pipeline, says bank
If you're looking for a solid growth story in the pharma sector, AstraZeneca PLC (LSE:AZN)Â should be on your radar. Berenberg's latest update paints a bright picture, highlighting some exciting pipeline readouts that haven't yet made their way into the share price.
AstraZeneca: Market isn't pricing in the potential of late-stage pipeline, says bank
If you're looking for a solid growth story in the pharma sector, AstraZeneca PLC (LSE:AZN)Â should be on your radar. Berenberg's latest update paints a bright picture, highlighting some exciting pipeline readouts that haven't yet made their way into the share price.
07/08 11:46 EST - zacks.com
AstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth?
AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5.6 billion in sales.
AstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth?
AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5.6 billion in sales.
07/08 07:00 EST - seekingalpha.com
AstraZeneca: Just What The Doctor Ordered
AstraZeneca is a classic GARP stock with robust growth, an undervalued share price, and a strong drug pipeline supporting future earnings expansion. Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations, and key therapy areas like oncology and respiratory are driving...
AstraZeneca: Just What The Doctor Ordered
AstraZeneca is a classic GARP stock with robust growth, an undervalued share price, and a strong drug pipeline supporting future earnings expansion. Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations, and key therapy areas like oncology and respiratory are driving...
07/04 09:36 EST - zacks.com
AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer
AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.
AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer
AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.
07/04 05:10 EST - seekingalpha.com
Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain
Summit Therapeutics is in advanced talks with AstraZeneca for a potential $15B licensing deal for ivonescimab, boosting its cash runway and strategic position. Ivonescimab shows strong PFS data versus Keytruda in NSCLC, but mixed OS results could delay U.S. approval and complicate regulatory...
Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain
Summit Therapeutics is in advanced talks with AstraZeneca for a potential $15B licensing deal for ivonescimab, boosting its cash runway and strategic position. Ivonescimab shows strong PFS data versus Keytruda in NSCLC, but mixed OS results could delay U.S. approval and complicate regulatory...
07/04 03:15 EST - proactiveinvestors.co.uk
AstraZeneca wins EU approval for Imfinzi in early bladder cancer treatment
AstraZeneca PLC's (LSE:AZN) cancer drug Imfinzi has been approved in the European Union for use before and after surgery in patients with muscle-invasive bladder cancer, marking a significant step forward in treatment options for the disease. The approval means Imfinzi is now the first and only...
AstraZeneca wins EU approval for Imfinzi in early bladder cancer treatment
AstraZeneca PLC's (LSE:AZN) cancer drug Imfinzi has been approved in the European Union for use before and after surgery in patients with muscle-invasive bladder cancer, marking a significant step forward in treatment options for the disease. The approval means Imfinzi is now the first and only...
07/03 18:26 EST - fool.com
Why AstraZeneca Stock Got Thumped on Thursday
AstraZeneca (AZN -2.36%) might soon be on the hook for an eventual 11-figure payout, and investors weren't all that comfortable with this. A Bloomberg article published Thursday morning said that the company is pursuing what might end up being an expensive partnership with a biotech.
Why AstraZeneca Stock Got Thumped on Thursday
AstraZeneca (AZN -2.36%) might soon be on the hook for an eventual 11-figure payout, and investors weren't all that comfortable with this. A Bloomberg article published Thursday morning said that the company is pursuing what might end up being an expensive partnership with a biotech.
07/03 11:38 EST - youtube.com
Report: Summit in talks for $15 billion partnership with AstraZeneca
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on AstraZeneca
Report: Summit in talks for $15 billion partnership with AstraZeneca
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on AstraZeneca